China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
FREMONT, Calif., March 09, 2016 -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage specialty pharmaceutical company, today announced that Konstantinos Alataris, Ph.D., President and Chief Executive Officer of Zosano, will provide a company overview at the 28th Annual ROTH Conference on March 14, 2016. The presentation will take place at 8:00 a.m. PT at the Ritz Carlton Hotel in Laguna Niguel, California.
To access the presentation, please visit the Zosano website at www.zosanopharma.com. Under the "Investors" tab, select the link to "Events & Presentations."
About Zosano Pharma
Zosano Pharma Corporation is a clinical-stage specialty pharmaceutical company that has developed a proprietary transdermal microneedle patch system to deliver drug formulations through the skin for the treatment of a variety of indications. Zosano Pharma's microneedle patch system offers rapid onset, consistent drug delivery, improved ease of use and room-temperature stability, benefits that the company believes often are unavailable using oral formulations or injections. Zosano Pharma's microneedle patch system has the potential to deliver numerous medications for a wide variety of indications in commercially attractive markets. It has been tested in more than 400 patients with over 30,000 patches successfully applied to humans in Phase 1 and Phase 2 clinical studies. Learn more at www.zosanopharma.com.
Corporate Contact: Konstantinos Alataris President and Chief Executive Officer 510-745-1200 Investor Contact: Patti Bank Westwicke Partners 415-513-1284 [email protected] Media Contact: Jamie Lacey-Moreira 410-299-3310 [email protected]
